Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
More News: American Health | Avastin | Clinical Trials | Diabetes | Endocrinology | Eyes | Health | Lucentis | National Institutes of Health (NIH) | Ranibizumab Injection